We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
Read MoreHide Full Article
United Therapeutics (UTHR - Free Report) announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval to include data from the INCREASE study on the label of its pulmonary arterial hypertension (PAH) drug, Tyvaso for review. The pivotal phase III INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a lung disease for which no treatments are presently approved. Tyvaso is presently approved to treat PAH to improve exercise ability.
The FDA granted standard review to the sNDA and so a decision is expected in April 2021. If approved, the label update will increase Tyvaso's eligible U.S. population by more than 30,000 patients, which should drive sales of the drug higher.
The stock has risen 25.8% this year so far against the industry’s decrease of 6.3%.
In February, United Therapeutics had announced that the INCREASE study met its primary efficacy endpoint by showing that Tyvaso improved six-minute walk distance by 21 meters compared to placebo after being administered for 16 weeks. The study also met its key secondary endpoints.
Other than Tyvaso, which is an inhaled version of treprostinil, United Therapeutics markets three other PAH medicines in the United States: Remodulin, an injectable formulation of treprostinil; Orenitram, an oral version of treprostinil; and Adcirca tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. Please note that United Therapeutics bought exclusive rights to commercialize Adcirca (tadalafil) for PAH in the United States from Eli Lilly (LLY - Free Report) in November 2008. Eli Lilly markets tadalafil as Cialis for erectile dysfunction. Adcirca/Cialis lost exclusivity in 2018 and generic versions are available.
United Therapeutics is working on several late-stage PAH studies. Key phase III programs include autologous cell therapy (PAH - phase II/III SAPPHIRE study), Treprostinil Technosphere dry powder inhaler (PAH — phase III BREEZE study), Tyvaso in PAH patients who have COPD (phase III PERFECT study), and Ralinepag (PAH — phase III ADVANCE outcomes studies). Success in these studies may open up attractive market opportunities and address significant unmet clinical needs.
United Therapeutics currently carries a Zacks Rank #4 (Sell).
A couple of top-ranked small drugmakers include Pacira BioSciences (PCRX - Free Report) and Actinium Pharmaceuticals (ATNM - Free Report) . While Pacira has a Zacks Rank of 1, Actinium has a Zacks Rank #2 (Buy).
Pacira’s stock has risen 37.4% this year so far. Its earnings estimates for 2020 have increased 6.2% while that for 2021 have risen 5.5% over the past 30 days.
Actinium’s stock has risen 65.3% this year so far.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
United Therapeutics (UTHR - Free Report) announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval to include data from the INCREASE study on the label of its pulmonary arterial hypertension (PAH) drug, Tyvaso for review. The pivotal phase III INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a lung disease for which no treatments are presently approved. Tyvaso is presently approved to treat PAH to improve exercise ability.
The FDA granted standard review to the sNDA and so a decision is expected in April 2021. If approved, the label update will increase Tyvaso's eligible U.S. population by more than 30,000 patients, which should drive sales of the drug higher.
The stock has risen 25.8% this year so far against the industry’s decrease of 6.3%.
In February, United Therapeutics had announced that the INCREASE study met its primary efficacy endpoint by showing that Tyvaso improved six-minute walk distance by 21 meters compared to placebo after being administered for 16 weeks. The study also met its key secondary endpoints.
Other than Tyvaso, which is an inhaled version of treprostinil, United Therapeutics markets three other PAH medicines in the United States: Remodulin, an injectable formulation of treprostinil; Orenitram, an oral version of treprostinil; and Adcirca tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. Please note that United Therapeutics bought exclusive rights to commercialize Adcirca (tadalafil) for PAH in the United States from Eli Lilly (LLY - Free Report) in November 2008. Eli Lilly markets tadalafil as Cialis for erectile dysfunction. Adcirca/Cialis lost exclusivity in 2018 and generic versions are available.
United Therapeutics is working on several late-stage PAH studies. Key phase III programs include autologous cell therapy (PAH - phase II/III SAPPHIRE study), Treprostinil Technosphere dry powder inhaler (PAH — phase III BREEZE study), Tyvaso in PAH patients who have COPD (phase III PERFECT study), and Ralinepag (PAH — phase III ADVANCE outcomes studies). Success in these studies may open up attractive market opportunities and address significant unmet clinical needs.
United Therapeutics currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A couple of top-ranked small drugmakers include Pacira BioSciences (PCRX - Free Report) and Actinium Pharmaceuticals (ATNM - Free Report) . While Pacira has a Zacks Rank of 1, Actinium has a Zacks Rank #2 (Buy).
Pacira’s stock has risen 37.4% this year so far. Its earnings estimates for 2020 have increased 6.2% while that for 2021 have risen 5.5% over the past 30 days.
Actinium’s stock has risen 65.3% this year so far.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>